DDInter1233 DDInter1352
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931]
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Bisacodyl
Bisacodyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Mitotane {u} (Compound) resembles {v} (Compound) Delorazepam
Delorazepam {u} (Compound) resembles {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tacrine
Tacrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Mitotane {u} (Compound) resembles {v} (Compound) Delorazepam
Delorazepam {u} (Compound) resembles {v} (Compound) Midazolam
Midazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eslicarbazepine
Eslicarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Mitotane {u} (Compound) resembles {v} (Compound) Delorazepam
Delorazepam {u} (Compound) resembles {v} (Compound) Amoxapine
Amoxapine {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clomipramine
Clomipramine {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramelteon
Ramelteon {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Mitotane {u} (Compound) binds {v} (Gene) CYP11B1
CYP11B1 {u} (Gene) is bound by {v} (Compound) Fluconazole
Fluconazole {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Mitotane {u} (Compound) binds {v} (Gene) CYP11A1
CYP11A1 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Mitotane (Compound) resembles Delorazepam (Compound) and Delorazepam (Compound) resembles Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Osimertinib
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tacrine and Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Mitotane (Compound) resembles Delorazepam (Compound) and Delorazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine and Eslicarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Mitotane (Compound) resembles Delorazepam (Compound) and Delorazepam (Compound) resembles Amoxapine (Compound) and Amoxapine may lead to a major life threatening interaction when taken with Osimertinib
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine may lead to a major life threatening interaction when taken with Osimertinib
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon and Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Mitotane (Compound) binds CYP11B1 (Gene) and CYP11B1 (Gene) is bound by Fluconazole (Compound) and Fluconazole may lead to a major life threatening interaction when taken with Osimertinib
Mitotane (Compound) binds CYP11A1 (Gene) and CYP11A1 (Gene) is bound by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib